South Korea
· Delayed Price · Currency is KRW S.Biomedics Statistics
Total Valuation
S.Biomedics has a market cap or net worth of KRW 356.86 billion. The enterprise value is 365.20 billion.
| Market Cap | 356.86B |
| Enterprise Value | 365.20B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
S.Biomedics has 11.47 million shares outstanding. The number of shares has increased by 9.52% in one year.
| Shares Outstanding | 11.47M |
| Shares Change (YoY) | +9.52% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 21.98% |
| Owned by Institutions (%) | 5.17% |
| Float | 7.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.69 |
| PB Ratio | 160.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -37.37 |
| EV / Sales | 30.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -50.01 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 1.37.
| Current Ratio | 1.40 |
| Quick Ratio | 1.03 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.51 |
| Interest Coverage | -7.44 |
Financial Efficiency
Return on equity (ROE) is -77.31% and return on invested capital (ROIC) is -18.03%.
| Return on Equity (ROE) | -77.31% |
| Return on Assets (ROA) | -12.90% |
| Return on Capital (ROIC) | -18.03% |
| Revenue Per Employee | 228.87M |
| Profits Per Employee | -187.91M |
| Employee Count | 52 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +199.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +199.42% |
| 50-Day Moving Average | 31,732.00 |
| 200-Day Moving Average | 25,096.30 |
| Relative Strength Index (RSI) | 45.40 |
| Average Volume (20 Days) | 213,054 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.Biomedics had revenue of KRW 11.90 billion and -9.77 billion in losses. Loss per share was -860.06.
| Revenue | 11.90B |
| Gross Profit | 5.91B |
| Operating Income | -6.58B |
| Pretax Income | -9.22B |
| Net Income | -9.77B |
| EBITDA | -4.89B |
| EBIT | -6.58B |
| Loss Per Share | -860.06 |
Balance Sheet
The company has 8.54 billion in cash and 11.06 billion in debt, giving a net cash position of -2.52 billion or -219.55 per share.
| Cash & Cash Equivalents | 8.54B |
| Total Debt | 11.06B |
| Net Cash | -2.52B |
| Net Cash Per Share | -219.55 |
| Equity (Book Value) | 8.05B |
| Book Value Per Share | 193.94 |
| Working Capital | 3.76B |
Cash Flow
In the last 12 months, operating cash flow was -5.87 billion and capital expenditures -1.43 billion, giving a free cash flow of -7.30 billion.
| Operating Cash Flow | -5.87B |
| Capital Expenditures | -1.43B |
| Free Cash Flow | -7.30B |
| FCF Per Share | -636.45 |
Margins
Gross margin is 49.70%, with operating and profit margins of -55.25% and -82.10%.
| Gross Margin | 49.70% |
| Operating Margin | -55.25% |
| Pretax Margin | -77.49% |
| Profit Margin | -82.10% |
| EBITDA Margin | -41.09% |
| EBIT Margin | -55.25% |
| FCF Margin | -61.36% |
Dividends & Yields
S.Biomedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.52% |
| Shareholder Yield | -9.52% |
| Earnings Yield | -2.77% |
| FCF Yield | -2.05% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.Biomedics has an Altman Z-Score of 1.4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.4 |
| Piotroski F-Score | n/a |